Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Children's Hospital of Philadelphia
- Registration Number
- NCT00978146
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
- Conditions
- Interventions
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Istituto Scientifico H. San Raffaele
- Target Recruit Count
- 76
- Registration Number
- NCT00904735
- Locations
- 🇮🇹
Azienda Ospedaliero Careggi, Florence, Italy
🇮🇹Ospedale Civile di Rovigo, Rovigo, Italy
🇮🇹Ospedale Civile Avellino, Avellino, Italy
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2020-08-20
- Target Recruit Count
- 163
- Registration Number
- NCT00890396
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2008-12-16
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT00809042
- Locations
- 🇮🇷
Hematology Research Center of Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 8
- Registration Number
- NCT00706810
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
- Conditions
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 29
- Registration Number
- NCT00568698
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
- Conditions
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 27
- Registration Number
- NCT00568802
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT00532883
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸University of California Davis, Sacramento, California, United States
🇺🇸Children's Hospital and Research Center, Oakland, California, United States
Hydroxyurea in Young Children With Sickle Cell Anemia
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Duke University
- Target Recruit Count
- 14
- Registration Number
- NCT00519701
- Locations
- 🇺🇸
Duke University Medican Center, Durham, North Carolina, United States
A Trial of Hydroxyurea in Spinal Muscular Atrophy
- Conditions
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.